Are circulating levels of CRP compared to IL-6 and PCT still relevant in intensive care unit patients?;Spielen CRP-Spiegel neben IL-6 und PCT noch eine Rolle für Patienten auf Intensivstationen?

LaboratoriumsMedizin

Volumn 37, Issue 1, 2013, Pages 1-11

  Boenisch, Sylvia ^a   Fae, Peter ^b   Drexel, Heinz ^c   Walli, Autar K ^d   Fraunberger, Peter ^a  

^a Medizinisches Zentrallabor ^*  (Austria)

^b Landeskrankenhaus Feldkirch   (Austria)

^c Vorarlberger Institut Zur Erforschung und Behandlung von Erkrankungen des Gefäßsystems   (Austria)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

C reactive protein (CRP); C reaktive Protein (CRP); Entz ndungsmarker; infection; Infektion; inflammatory marker; intensive care; Intensivstation; Interleukin 6 (IL 6); interleukin 6 (IL 6); Procalcitonin (PCT); procalcitonin (PCT); Sepsis; sepsis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; PROCALCITONIN;

ARTICLE; BACTERIAL INFECTION; EMERGENCY PATIENT; HUMAN; INTENSIVE CARE; PATIENT MONITORING; PROGNOSIS;

BACTERIA (MICROORGANISMS);

EID: 84875413621     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labmed-2012-0010     Document Type: Article

References (122)

1. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38:189-97.
2. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
3. Pepys MB. C-reactive protein fifty years on. Lancet 1981;1:653-7.
4. Chirico G, Loda C. Laboratory aid to the diagnosis and therapy of infection in the neonate. Pediatr Rep 2011;3:e1.
5. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512-25.
6. Muller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001;86:396-404.
7. Linscheid P, Seboek D, Nylen ES, Langer I, Schlatter M, Becker KL, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003;144:5578-84.
8. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8.
9. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000;28:977-83.
10. Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000;28:458-61.
11. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79:1605-8.
12. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med 1998;24:888-9.
13. Steinwald PM, Whang KT, Becker KL, Snider RH, Nylen ES, White JC. Elevated calcitonin precursor levels are related to mortality in an animal model of sepsis. Crit Care (Lond) 1999;3:11-6.
14. Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998;26:1001-6.
15. Whang KT, Vath SD, Becker KL, Snider RH, Nylen ES, Muller B, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock 2000;14:73-8.
16. de Werra I, Jaccard C, Corradin SB, Chiolero R, Yersin B, Gallati H, et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997;25:607-13.
17. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000;19:679-87; quiz 88.
18. Muller B, Peri G, Doni A, Perruchoud AP, Landmann R, Pasqualini F, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002;72:643-9.
19. Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics 2003;112:1054-60.
20. Suárez-Santamaría M, Santolaria F, Pérez- Ramírez A, Alemán-Valls MR, Martínez-Riera A, González-Reimers E, et al. Prognostic value of inflammatory markers (notably cytokines and procalcitonin), nutritional assessment, and organ function in patients with sepsis. Eur Cytokine Netw 2010;21:19-26.
21. Monneret G, Doche C, Durand DV, Lepape A, Bienvenu J. Procalcitonin as a specific marker of bacterial infection in adults. Clin Chem Lab Med 1998;36:67-8.
22. Oczenski W, Fitzgerald RD, Schwarz S. Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period. Eur J Anaesthesiol 1998;15:202-9.
23. de Bont ES, Vellenga E, Swaanenburg J, Kamps W. Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever? Infection 2000;28:398-400.
24. Marc E, Menager C, Moulin F, Stos B, Chalumeau M, Guerin S, et al. Procalcitonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak. Arch Pediatr 2002;9:358-64.
25. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17 [erratum] 2005;40:1386.
26. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402.
27. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-7.
28. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
29. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs. a standard approach for acute respiratory tract infections in primary care. Arch Internal Med 2008;168:2000-7; discussion 2007-8.
30. Christ-Crain M, Stolz D, Bingisser R, Huber P, Leuppi J, Müller C, et al. Procalcitonin guidance significantly reduces antibiotic duration in community-acquired pneumonia. Proc 25 th Int. Congress of Intensive Care and Emergency Medicine (ISICEM), Brussels, 2005.
31. Zetterstrom M, Sundgren-Andersson AK, Ostlund P, Bartfai T. Delineation of the proinflammatory cytokine cascade in fever induction. Ann N Y Acad Sci 1998;856:48-52.
32. Volante E, Moretti S, Pisani F, Bevilacqua G. Early diagnosis of bacterial infection in the neonate. J Matern Fetal Neonatal Med 2004;16:13-6.
33. Fraunberger P, Wang Y, Holler E, Parhofer KG, Nagel D, Walli AK, et al. Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever. Shock 2006;26:10-2.
34. Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008;177:1242-7.
35. Groeneveld AB, Tacx AN, Bossink AW, van Mierlo GJ, Hack CE. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol 2003;106:106-15.
36. Martin C, Boisson CH, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-α and interleukin-6) after sepsis shock, hemorrhagic shock, and trauma. Crit Care Med 1997;25:1813-9.
37. Van Dissel J, van Langevelde P, Westendorp R, Kwappenberg K, Fröhlich M. Antiinflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-3.
38. Peteiro-Cartelle FJ, Alvarez-Jorge A. Dynamic profiles of interleukin-6 and the soluble form of CD25 in burned patients. Burns 1999;6:487-91.
39. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. J Am Med Assoc 1995;274:58-65.
40. Wenzel RP, Wong MT. Managing antibiotic use-impact of infection control. Clin Infect Dis 1999;28:1126-7.
41. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9.
42. Guillemot D, Courvalin P. Better control of antibiotic resistance. Clin Infect Dis 2001;33:542-7.
43. Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002;49:31-40.
44. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-90.
45. Enguix A, Rey C, Concha A, Medina A, Coto D, Dieguez MA. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 2001;27:211-5.
46. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15.
47. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003;123:2043-9.
48. Chauveau P, Level C, Lasseur C, Bonarek H, Peuchant E, Montaudon D, et al. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a 2-year prospective study. J Ren Nutr 2003;13:137-43.
49. Ho KM, Lee KY, Dobb GJ, Webb SA. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a prospective cohort study. Intensive Care Med 2008;34:481-7.
50. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:10.
51. Jensen JU, Heslet L, Jensen TH, Espersen K, Steff ensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34:2596-602.
52. Silvestre J, Coelho L, Póvoa P. Should C-reactive protein concentration at ICU discharge be used as a prognostic marker ? BMC Anesthesiol 2010;10:17.
53. Silvestre J, Póvoa P, Coelho L, Almeida E, Moreira P, Fernandes A, et al. Is C-reactive protein a good prognostic marker in septic patients ? Intensive Care Med 2009;35: 909-13.
54. Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Brückner U. Is Interleukin 6 an early marker of injury severity following major trauma humans? Arch Surg 2000;135:291-5.
55. Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989;61:588-602.
56. Fraunberger P, Walli AK, Seidel D. Zytokinanalytik Was ist machbar-was ist sinnvoll ? Internist 2001;42:35-46.
57. Steinmetz HAT, Herbertz A, Bertram M, Diehl V. Increase in interleukin-6 serum level preceding fever in granulocytopenia and correlation with death from sepsis. J Infect Dis 1995;171:225-8.
58. Moscovitz H, Shofer F, Mignott H, Behrman A, Kilpatrick L. Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Crit Care Med 1994;22:1102-7.
59. Le Moine O, Deviere J, Devaster JM, Crusiaux A, Durand F, Bernuau J, et al. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. J Hepatol 1994;20:819-24.
60. K üster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, et al. Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet 1998;352:1271-7.
61. Kallman J, Ekholm L, Eriksson M, Malmstrom B, Schollin J. Contribution of interleukin-6 in distinguishing between mild respiratory disease and neonatal sepsis in the newborn infant. Acta Paediatr 1999;88:880-4.
62. Magudumana MO, Ballot DE, Cooper PA, Trusler J, Cory BJ, Viljoen E, et al. Serial interleukin 6 measurements in the early diagnosis of neonatal sepsis. J Trop Pediatr 2000;46:267-71.
63. Tang G, Kuo C, Yen T, Kuo H, Chan K, Yien H, et al. Perioperative plasma concentrations of tumor necrosis factor-and interleukin-6 in infected patients. Crit Care Med 1996;24:423-8.
64. Kragsbjerg P, Holmberg H, Vikerfors T. Serum concentrations of interleukin-6, tumour necrosis factor-alpha, and C-reactive protein in patients undergoing major operations. Eur J Surg 1995;161:17-22.
65. Ng PC. Diagnostic markers of infection in neonates. Arch Dis Child Fetal Neonatal Ed 2004;89:F229-35.
66. LaPar DJ, Rosenberger LH, Walters DM, Hedrick TL, Swenson BR, Young JS, et al. Severe traumatic head injury affects systemic cytokine expression. J Am Coll Surg 2012;214:478-86; discussion 486-8.
67. Lin JS, Tzeng CH, Hao TC, Hu HY, Ho YT, Lyou JY, et al. Cytokine release in febrile non-haemolytic red cell transfusion reactions. Vox Sang 2002;82:156-60.
68. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004;23:539-44.
69. Miguel-Bayarri V, Casanoves-Laparra EB, Pall ás-Beneyto L, Sancho-Chinesta S, Martín-Osorio LF, Tormo-Calandín C, et al. Prognostic value of the biomarkers procalcitonin, interleukin-6 and C-reactive protein in severe sepsis. Med Intensiva 2012;36:556-62.
70. Jess P, Schulz K, Bendtzen K, Nielson OH. Systemic inflammatory responses during laparoscopic and open inguinal hernia repair: a randomised prospectiv study. Eur J Surg 2000;166:540-4.
71. Stecker W, Gebhard F, Rager J, Bruckner UB, Steinbach G, Kinzl L. Early biochemical characterization of soft-tissue trauma and fracture trauma. J Trauma 1999;47:358-64.
72. Wunder C, Eichelbronner O, Roewer N. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis ? A comparison with APACHE III and SAPS II. Inflamm Res 2004;53:158-63.
73. Haasper C, Kalmbach M, Dikos GD, Meller R, Müller C, Krettek C, et al. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. Technol Health Care 2010;18:89-100.
74. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 2002;20:1-9.
75. Whicher J, Bienvenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001;38:483-93.
76. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
77. World Health Organization (WHO). Removing obstables to healthy development. Geneva: WHO; 1999.
78. Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med 2002;347:2039-45.
79. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann Intern Med 2000;133:981-91.
80. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34:1996-2003.
81. Iapichino G, Marzorati S, Umbrello M, Baccalini R, Barassi A, Cainarca M, et al. Daily monitoring of biomarkers of sepsis in complicated long-term ICU-patients: can it support treatment decisions ? Minerva Anestesiol 2010;76:814-23.
82. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 2011;66:ii33-40.
83. Tsalik EL, Jaggers LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, et al. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med 2012;43:97-106.
84. Gendrel D, Raymond J, Assicot M, Moulin F, Iniguez JL, Lebon P, et al. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997;24:1240-2.
85. Viallon A, Zeni F, Lambert C, Pozzetto B, Tardy B, Venet C, et al. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis 1999;28:1313-6.
86. Rau B, Steinbach G, Gansauge F, Mayer JM, Grunert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997;41:832-40.
87. Bihari D. Monitoring procalcitonin is of value in acute pancreatitis. Br Med J 2004;329:232.
88. Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In criticallill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, IL-6, or LBP. Crit Care Res Pract 2011;2011:594645.
89. Balc IC, Sungurtekin H, Gü rses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003;7:85-90.
90. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Geneva sepsis network. diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402.
91. de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008;34:518-22.
92. de Kruif MD, Lemaire LC, Giebelen IA, van Zoelen MA, Pater JM, van den Pangaart PS, et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol 2007;178:1845-51.
93. Christ-Crain M, Müller B. Procalcitonin in bacterial infections- hype, hope, more or less ? Swiss Med Wkly 2005;135: 451-60.
94. van Dissel JT. Procalcitonin: what should be its role in the clinical management of febrile patients admitted to the hospital ? Clin Infect Dis 2003;36:824-5; author reply 826-7.
95. Debard AL, Vautrin C, Pariset C, Bienvenu J, Monneret G. High serum procalcitonin levels do not predict bacteremia in adult patients with acute fever. Clin Infect Dis 2003;36:825-6; author reply 826-7.
96. Mueller C, Huber P, Laifer G, Mueller B, Perruchoud AP. Procalcitonin and the early diagnosis of infective endocarditis. Circulation 2004;109:1707-10.
97. Mueller C, Christ-Crain M, Muller B. What cardiologists do need to know about procalcitonin. Clin Lab 2005;51:1-4.
98. Watkin RW, Harper LV, Vernallis AB, Lang S, Lambert PA, Ranasinghe AM, et al. Pro-inflammatory cytokines IL6, TNF-alpha, IL1beta, procalcitonin, lipopolysaccharide binding protein and C-reactive protein in infective endocarditis. J Infect 2007;55:220-5.
99. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-7.
100. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007;11:R38.
101. Póvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. C-reactive protein as a marker of ventilatorassociated pneumonia resolution: a pilot study. Eur Respir J 2005;25:804-12.
102. Póvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 2005;11:101-8.
103. Christ-Crain M, Schuetz P, Huber AR, Müller B. Procalcitonin und seine Bedeutung für die Diagnose bakterieller Infektionen. J Lab Med 2008;32,6:425-33.
104. Shehabi Y, Seppelt I. Pro/con debate: is procalcitonin useful for guiding antibiotic decision making in critically ill patients ? Crit Care 2008;12:211.
105. Wanner GA, Keel M, Steckholzer U, Beier W, Stocker R, Ertel W. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000;28:950-7.
106. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schüttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998;24: 680-4.
107. Becker KL, O'Neil WJ, Snider RH Jr, Nylen ES, Moore CF, Jeng J, et al. Hypercalcitonemia in inhalation burn injury: a response of the pulmonary neuroendocrine cell ? Anat Rec 1993;236:136-8, 172-3; discussion 138-43.
108. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14:203.
109. Limper M, de Kruif MD, Duits AJ, Brandjes DP, van Gorp EC. The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect 2010;60:409-16.
110. World Health Organization (WHO). Overcoming antimicrobial resistance. Geneva: WHO; 2000.
111. Liaudat S, Dayer E, Praz G, Bille J, Troillet N. Usefulness of procalcitonin serum level for the diagnosis of bacteremia. Eur J Clin Microbiol Infect Dis 2001;20:524-7.
112. Park BH, Kang YA, Park MS, Jung WJ, Lee SH, Lee SK, et al. Delta neutrophil index as an early marker of disease severity in critically ill patients with sepsis. BMC Infect Dis 2011;11:299.
113. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008;177:498-505.
114. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009;394:221-6.
115. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients'exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74.
116. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010;36:601-7.
117. Charles PE, Tinel C, Barbar S, Aho S, Prin S, Doise JM, et al. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009;13:R38.
118. Schmit X, Vincent JL. The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection 2008;36:213-9.
119. Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008;63:447-52.
120. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402.
121. Fraunberger P, Walli AK. Biomarker bei Sepsis und Entzündung. J Lab Med 2007;31:294-309.
122. Dahaba AA, Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator ? Minerva Anestesiol 2009;75:447-52.